NASDAQ:HOOKHookipa Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.32 +0.02 (+0.19 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$10.05Now: $10.32▼$10.8850-Day Range$9.74MA: $11.16▼$12.1052-Week Range$5.80Now: $10.32▼$14.37Volume20,300 shsAverage Volume76,861 shsMarket Capitalization$225.23 millionP/E RatioN/ADividend YieldN/ABeta1.5 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Hookipa Pharma has a potential upside of 84.1% from its current price of $10.32.Amount of Analyst CoverageHookipa Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesHookipa Pharma has received 43 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHookipa Pharma has received 41 “underperform” votes. (Add your “underperform” vote.)Community SentimentHookipa Pharma has received 51.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote “Outperform” if you believe HOOK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,638.00 in company stock.Percentage Held by InsidersOnly 4.02% of the stock of Hookipa Pharma is held by insiders.Percentage Held by InstitutionsOnly 31.45% of the stock of Hookipa Pharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Hookipa Pharma are expected to decrease in the coming year, from ($1.81) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOOK Previous Symbol CUSIPN/A CIKN/A Webwww.hookipapharma.com Phone431-890-6360Debt Debt-to-Equity Ratio0.08 Current Ratio7.85 Quick Ratio7.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$11.94 million Price / Sales18.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book1.89Profitability EPS (Most Recent Fiscal Year)($2.41) Net Income$-43,040,000.00 Net Margins-333.02% Return on Equity-36.53% Return on Assets-29.76%Miscellaneous Employees56 Outstanding Shares21,825,000Market Cap$225.23 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:HOOK Rates by TradingView Receive HOOK News and Ratings via Email Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions How has Hookipa Pharma's stock been impacted by COVID-19 (Coronavirus)? Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HOOK shares have increased by 11.6% and is now trading at $10.32. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Hookipa Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hookipa Pharma. When is Hookipa Pharma's next earnings date? Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Hookipa Pharma. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.01. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.36 million. Hookipa Pharma had a negative net margin of 333.02% and a negative return on equity of 36.53%. View Hookipa Pharma's earnings history. What price target have analysts set for HOOK? 2 analysts have issued 12 month target prices for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price. View analysts' price targets for Hookipa Pharma. Has Hookipa Pharma been receiving favorable news coverage? News coverage about HOOK stock has trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hookipa Pharma earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Hookipa Pharma. Are investors shorting Hookipa Pharma? Hookipa Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 723,700 shares, an increase of 300.5% from the May 31st total of 180,700 shares. Based on an average daily trading volume, of 78,700 shares, the days-to-cover ratio is currently 9.2 days. Currently, 6.2% of the shares of the company are sold short. View Hookipa Pharma's Current Options Chain. Who are some of Hookipa Pharma's key competitors? Some companies that are related to Hookipa Pharma include Repare Therapeutics (RPTX), Retrophin (RTRX), Gossamer Bio (GOSS), Legend Biotech (PLRX), Cara Therapeutics (CARA), Phathom Pharmaceuticals (PHAT), Kura Oncology (KURA), Generation Bio (GBIO), Dynavax Technologies (DVAX), Endo International (ENDP), Morphic (MORF), Stoke Therapeutics (STOK), G1 Therapeutics (GTHX), Assembly Biosciences (ASMB) and ImmunoGen (IMGN). View all competitors. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Atreca (BCEL), Homology Medicines (FIXX), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Stoke Therapeutics (STOK), Akero Therapeutics (AKRO) and Tcr2 Therapeutics (TCRR). Who are Hookipa Pharma's key executives? Hookipa Pharma's management team includes the following people: Mr. Joern Aldag, Pres, CEO & Director (Age 60)Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)Dr. Reinhard Kandera, CFO & Director (Age 50)Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)Mrs. Nina Waibel, Communications & Investor Relations Mang. When did Hookipa Pharma IPO? (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager. What is Hookipa Pharma's stock symbol? Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK." How do I buy shares of Hookipa Pharma? Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Hookipa Pharma's stock price today? One share of HOOK stock can currently be purchased for approximately $10.32. How big of a company is Hookipa Pharma? Hookipa Pharma has a market capitalization of $225.23 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe. What is Hookipa Pharma's official website? The official website for Hookipa Pharma is www.hookipapharma.com. How can I contact Hookipa Pharma? Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
